R&D Trends

Amgen, Merck collaborate on non-Hodgkin’s lymphoma

Monday, December 7, 2015

Amgen and Merck, known as MSD outside the U.S. and Canada, today announced a cancer immunotherapy collaboration to support a phase Ib/III study investigating BLINCYTO (blinatumomab) in combination with KEYTRUDA (pembrolizumab) in patients with diffuse large B-cell lymphoma (DLBCL), which is the most common type of non-Hodgkin’s lymphoma.

[Read More]